COSCIENS Biopharma’s Unexpected Trial Outcomes
Company Announcements

COSCIENS Biopharma’s Unexpected Trial Outcomes

COSCIENS Biopharma (TSE:CSCI) has released an update.

COSCIENS Biopharma Inc. revealed unexpected Phase 3 trial results for macimorelin, a diagnostic tool for Childhood Onset Growth Hormone Deficiency, which did not meet the primary efficacy endpoint. Despite this, the trial confirmed the safety of macimorelin and its ability to stimulate growth hormone release in children. The company plans further analysis and discussions with health authorities while continuing to market macimorelin for adult use.

For further insights into TSE:CSCI stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskCOSCIENS Biopharma Restructures Board After Resignation
TheFlyCosciens Biopharma director Carolyn Egbert resigns
TipRanks Auto-Generated NewsdeskCOSCIENS Biopharma Welcomes New Board Director
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App